{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+with+adjuvant&page=2", "query": { "intervention": "Placebo with adjuvant", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+with+adjuvant&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T22:02:04.852Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04789577", "title": "A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "FLU-Q-PAN H7N9 Formulation 1", "type": "BIOLOGICAL" }, { "name": "FLU-Q-PAN H7N9 Formulation 2", "type": "BIOLOGICAL" }, { "name": "FLU-Q-PAN H7N9 Formulation 3", "type": "BIOLOGICAL" }, { "name": "AS03B", "type": "BIOLOGICAL" }, { "name": "AS03A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 833, "start_date": "2021-03-16", "completion_date": "2022-09-12", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 8, "location_summary": "Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more", "locations": [ { "city": "Stockbridge", "state": "Georgia" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Cary", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04789577" }, { "nct_id": "NCT04025879", "title": "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 461, "start_date": "2019-11-05", "completion_date": "2027-07-31", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 15, "location_summary": "Tampa, Florida • Atlanta, Georgia • Augusta, Georgia + 11 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04025879" }, { "nct_id": "NCT03343626", "title": "Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Virus, Zika", "Zika Virus Disease", "Flavivirus Infections", "Healthy Participants" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PIZV", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 271, "start_date": "2017-11-13", "completion_date": "2020-11-24", "has_results": true, "last_update_posted_date": "2022-02-11", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 7, "location_summary": "Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Endwell", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03343626" }, { "nct_id": "NCT02557633", "title": "A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Allergic Rhinitis" ], "interventions": [ { "name": "Grass MATA MPL 10200", "type": "BIOLOGICAL" }, { "name": "Grass MATA MPL 18200", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Allergy Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 29, "start_date": "2015-08", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 2, "location_summary": "Neptune City, New Jersey • Newark, New Jersey", "locations": [ { "city": "Neptune City", "state": "New Jersey" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02557633" }, { "nct_id": "NCT01594320", "title": "A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza (Pandemic)" ], "interventions": [ { "name": "Monovalent Avian Influenza VLP (H5N1)", "type": "BIOLOGICAL" }, { "name": "Monovalent Avian Influenza VLP (H5N1); Adjuvant", "type": "BIOLOGICAL" }, { "name": "Saline placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 333, "start_date": "2012-04", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 5, "location_summary": "Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594320" }, { "nct_id": "NCT07142278", "title": "DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer Disease", "Alzheimer Disease (AD)", "Preclinical Alzheimer's Disease" ], "interventions": [ { "name": "DUVAX 200 µg", "type": "BIOLOGICAL" }, { "name": "DUVAX 400 µg", "type": "BIOLOGICAL" }, { "name": "Placebo (Adjuvant only)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nuravax, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "40 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2026-10-20", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 1, "location_summary": "Miami Lakes, Florida", "locations": [ { "city": "Miami Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07142278" }, { "nct_id": "NCT02935686", "title": "A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140 plus adjuvant", "type": "BIOLOGICAL" }, { "name": "Clade C gp140/Mosaic gp140 plus adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "gp140 HIV Bivalent Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2017-03-31", "completion_date": "2023-11-22", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02935686" }, { "nct_id": "NCT03847428", "title": "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "150 Years", "sex": "ALL", "summary": "18 Years to 150 Years" }, "enrollment_count": 908, "start_date": "2019-04-29", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03847428" }, { "nct_id": "NCT00280033", "title": "H5 Adult - Chiron Study of Bird Flu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Aluminum hydroxide", "type": "BIOLOGICAL" }, { "name": "Inactivated Influenza A/H5N1 Vaccine (Chiron)", "type": "BIOLOGICAL" }, { "name": "MF-59", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 394, "start_date": "2006-02", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-09-13", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 4, "location_summary": "Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00280033" }, { "nct_id": "NCT01709019", "title": "RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus (RSV)" ], "interventions": [ { "name": "Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)", "type": "BIOLOGICAL" }, { "name": "Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)", "type": "BIOLOGICAL" }, { "name": "High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)", "type": "BIOLOGICAL" }, { "name": "High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)", "type": "BIOLOGICAL" }, { "name": "Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 220, "start_date": "2012-10", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-09-29T22:02:04.852Z", "location_count": 4, "location_summary": "Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709019" } ] }